- The disease
- Prostate cancer is the most commonly diagnosed cancer in men in many Western countries. A key clinical challenge is accurately locating where cancer has spread, particularly when prostate-specific antigen (PSA) levels rise after initial treatment, a situation called biochemical recurrence. Identifying the precise sites of disease guides decisions about further treatment. PSMA is a protein that is expressed at high levels on the surface of most prostate cancer cells, making it a useful target for imaging.
- What the asset is trying to do
- Illuccix (68Ga-PSMA-11) is a radiopharmaceutical diagnostic agent. It consists of a molecule that binds to PSMA on prostate cancer cells, attached to a radioactive isotope, gallium-68. When administered to a patient, it accumulates at sites where PSMA-expressing cancer cells are present. A PET scanner then detects the radioactive signal, producing images that show where in the body those cells are located. This approach differs from conventional imaging such as CT or bone scans, which detect anatomical changes rather than targeting a specific protein on cancer cells.
- What the trial is measuring, and why it matters
- As an approved product, Illuccix has already completed the pivotal clinical trials required for regulatory clearance. Ongoing investigator-sponsored and company-associated trials that include PSMA PET imaging as an intervention are examining its use in guiding treatment decisions, such as directing radiation therapy (per ClinicalTrials.gov NCT04402151). Endpoints in those studies include imaging-based detection rates and clinical decision impact. The primary completion date for NCT04402151 is listed as 2027-12-31 (per ClinicalTrials.gov NCT04402151).
- Efficacy benchmarks in this setting
- For the approved indication of PSMA PET imaging in biochemical recurrence of prostate cancer, the pivotal SPOTLIGHT and CONDOR trials of another approved PSMA PET agent, 18F-DCFPyL (Pylarify), reported correct localisation rates (CLR) of 84.8% and 84% respectively in patients with conventional imaging-negative biochemical recurrence (per Pienta et al, J Urol 2021 and Morris et al, J Nucl Med 2021). The pivotal data supporting US Food and Drug Administration (FDA) approval of 68Ga-PSMA-11 itself, including the UCLA/UCSF studies, showed correct localisation rates in the range reported for that program (per Fendler et al, J Nucl Med 2020). Because Illuccix is already approved, its own pivotal figures are not early-stage estimates; comparisons between different approved PSMA PET agents require prospective head-to-head data to be statistically meaningful.